# The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion

> **NCT00709657** · NA · TERMINATED · sponsor: **Medical University of Vienna** · enrollment: 8 (actual)

## Conditions studied

- Macular Degeneration
- Regional Blood Flow
- Vascular Endothelial Growth Factor

## Interventions

- **DRUG:** ranibizumab, bevacizumab or pegaptanib

## Key facts

- **NCT ID:** NCT00709657
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-03
- **Primary completion:** 2010-07
- **Final completion:** 2011-11
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2014-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00709657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00709657, "The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00709657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*